Biocryst Pharmaceuticals (BCRX) Other Working Capital Changes (2010 - 2026)

Biocryst Pharmaceuticals has reported Other Working Capital Changes for 17 years, with the latest figure at -$749000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes changed N/A year-over-year to -$749000.0; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (up 539.96% YoY), and the FY2025 full-year result was $7.8 million, changed N/A from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$749000.0, down from $1.9 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $5.9 million in Q3 2025, with the low at -$1.7 million in Q2 2024.
• Historically, Other Working Capital Changes has averaged $526937.5 across 5 years, with a median of $27000.0 in 2022.
• The largest YoY upside for Other Working Capital Changes was 430.55% in 2024 against a maximum downside of 3060.0% in 2024.
• Biocryst Pharmaceuticals' Other Working Capital Changes stood at $1.5 million in 2022, then slumped by 128.88% to -$419000.0 in 2023, then jumped by 430.55% to $1.4 million in 2024, then surged by 39.86% to $1.9 million in 2025, then tumbled by 138.67% to -$749000.0 in 2026.
• The last three Other Working Capital Changes figures came in at -$749000.0 (Q1 2026), $1.9 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.